Pasithea Wins FDA Fast Track for PAS-004 Cancer Drug
MIAMI, USA — April 1, 2026 Pasithea Therapeutics Corp. has announced that the U.S. Food and Drug Administration (FDA)...
PAS-004
Advertisement
NRG Therapeutics Expands Leadership to Accelerate Drug Pipeline
Stevenage, United Kingdom, December 1, 2025 NRG Therapeutics has announced the appointment of Dr. Paul Thompson as Chief Development...
Pasithea Raises $60M to Advance MEK Program and R&D Pipeline
Miami, Florida, November 28, 2025 Pasithea Therapeutics has announced the pricing of a $60 million public offering ,strengthening its...
Pasithea Activates UAB Clinical Site for PAS-004 NF1 Trial
MIAMI, November 4, 2025: Pasithea Therapeutics Corp. has announced the activation of a new clinical trial site at the...
Advertisement
